For tailored, single-person antisense oligonucleotides, FDA offers guidance on nonclinical testing
Over the last several years, a new wave of hyper-personalized therapies have quickly made their way into people, just one at a time, and often …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
